


The development of FVIII inhibitors in hemophilia A patients results from the inability of the immune system to mount a counteractive tolerogenic response



- All hemophilia A patients treated with FVIII develop an immune response to therapeutic FVIII
- The onset of neutralizing antibodies to FVIII results from an **inability to develop a counteractive antigen-specific tolerogenic response**, rather than from an exacerbated activation of the immune system at the time of FVIII administration

5-30% of the patients fail to develop active immune tolerance to FVIII